Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Tire Brands for Senior Drivers: Guaranteeing Security and Solace - 2Watch SpaceX launch powerful ocean-mapping satellite for Europe and NASA early Nov. 17
- 3Beyond oil: The crucial exports blocked by Hormuz closure
- 4Why are NASA's Artemis astronauts wearing orange? What are they bringing to space? What to know about the preparation for their moon mission.
- 5Brazil Passes Law to Use Seized Bitcoin, Crypto to Fund Public Security Measures
- Vehicle Lovers' Decision: Purchase A Reasonable Vehicle
- Accomplishing Balance between fun and serious activities: Procedures for a Better Life
- Tech for Efficiency: Applications and Apparatuses to Accomplish More
- Step by step instructions to Pick an Incineration Urn: Variables to Consider
- Pick Your Favored kind of books
- Experience Unrivaled Sound: Top Speakers You Really want to Hear
- Army commander convicted of Guinea stadium massacre dies in prison
- Transcript: NASA's Jared Isaacman on "Face the Nation with Margaret Brennan," April 5, 2026
- Europe could get 42 more days of summer by the year 2100 due to climate change
